News articles about Wright Medical Group (NASDAQ:WMGI) have been trending positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Wright Medical Group earned a coverage optimism score of 0.46 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 46.8736954587615 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
Top 10 Low Price Stocks To Buy Right Now: Heritage Financial Corporation(HFWA)
Heritage Financial Corporation operates as the bank holding company for Heritage Bank that provides various financial services to small and medium size businesses and general public. The company accepts various deposit products, such as noninterest demand accounts, negotiable order of withdrawal accounts, money market accounts, savings accounts, and certificates of deposit. Its loan portfolio includes commercial and industrial loans, owner-occupied and non-owner occupied commercial real estate loans, one-to-four family residential loans, real estate construction and land development loans, consumer loans, business lines of credit, term equipment financing, and term real estate loans, as well as commercial loans to real estate related industries and businesses in agricultural, healthcare, legal, and other professions. As of January 28, 2016, the company had a network of 66 branches located in Washington and Oregon. The company was formerly known as Heritage Financial Corporation, M.H.C. and changed its name to Heritage Financial Corporation in 1998. Heritage Financial Corporation was founded in 1994 and is headquartered in Olympia, Washington.
UBS Group AG lifted its position in Heritage Financial Corp (NASDAQ:HFWA) by 351.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,457 shares of the financial services provider’s stock after purchasing an additional 18,256 shares during the period. UBS Group AG owned about 0.07% of Heritage Financial worth $717,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Greene County Bancorp (NASDAQ: GCBC) and Heritage Financial (NASDAQ:HFWA) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations. Southern Missouri Bancorp (NASDAQ: SMBC) and Heritage Financial (NASDAQ:HFWA) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations. Get a free copy of the Zacks research report on Heritage Financial (HFWA) For more information about research offerings from Zacks Investment Research, visit Zacks.com Corindus Vascular Robotics, Inc. designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures. It offers CorPath 200 system, a robotic system that facilitates stent placement for percutaneous coronary intervention procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision. The company is headquartered in Waltham, Massachusetts. Shares of Corindus Vascular Robotics (NYSEMKT:CVRS), a robotic surgery company focused on vascular disease, rose as much as 14% in afternoon trading on Thursday. Shares were up about 10% as of 2:41 p.m. EST. The jump appears to be traceable to significant buying activity by one of the company's directors. Corindus Vascular Robotics Inc (NYSEMKT:CVRS)Q4 2018 Earnings Conference CallMarch 12, 2019, 4:30 p.m. ET Operator Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide. It operates through two segments, Citicorp and Citi Holdings. The Citicorp segment offers traditional banking services to retail customers through retail banking, commercial banking, Citi-branded cards, and Citi retail services. This segment also provides various banking, credit card lending, and investment services through a network of local branches, offices, and electronic delivery systems. In addition, it offers wholesale banking products and services to corporate, institutional, public sector, and high-net-worth clients. Further, this segment provides fixed income and equity sales and trading, foreign exchange, prime brokerage, derivative services, equity and fixed income research, corporate lending, investment banking and advisory services, private banking, cash management, trade finance, and securities services. As of December 31, 2015, it operated 2,994 branches in 24 countries. The Citi Holdings segment provides consumer loans; portfolio of securities, loans, and other assets; and retail alternative investment and other services. Citigroup Inc. was founded in 1812 and is based in New York, New York. Citigroup (NYSE:C) Q4 2018 Earnings CallApril 15, 2019 10:00 a.m. ET Operator The Dow Jones Industrial Average will rise only by a small margin after modest earnings reports from Goldman Sachs Group Inc. (NYSE: GS) and Citigroup Inc. (NYSE: C). Also there will be the analysts and investment bankers that cover real estate for the major firms including Goldman Sachs Group Inc. (NYSE: GS), JPMorgan Chase & Co. (NYSE: JPM), Citigroup Inc. (NYSE: C) and Bank of America Corp. (NYSE: BAC). Tortoise Investment Management LLC lowered its holdings in Citigroup Inc (NYSE:C) by 19.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 804 shares of the financial services provider’s stock after selling 200 shares during the period. Tortoise Investment Management LLC’s holdings in Citigroup were worth $42,000 at the end of the most recent reporting period. Helmerich & Payne, Inc. engages in the contract drilling of oil and gas wells. It provides drilling rigs, equipment, personnel, and camps on a contract basis to explore for and develop oil and gas from onshore areas and from fixed platforms, tension-leg platforms, and spars in offshore areas. The company operates through three segments: U.S. Land, Offshore, and International Land. The U.S. Land segment drills primarily in Oklahoma, California, Texas, Wyoming, Colorado, Louisiana, Mississippi, Pennsylvania, Ohio, Utah, New Mexico, Montana, North Dakota, West Virginia, and Nevada. The Offshore segment has drilling operations in the Gulf of Mexico and Equatorial Guinea. The International Land segment conducts drilling operations in Ecuador, Colombia, Argentina, Bahrain, the United Arab Emirates, and Mozambique. As of November 12, 2015, the company operated a fleet of 344 land rigs in the United States; 38 international land rigs; and 9 offshore platform rigs. The company also owns, develops, and operates commercial real estate properties; and researches and develops rotary steerable technology. Its real estate investments include a shopping center comprising approximately 441,000 leasable square feet; multi-tenant industrial warehouse properties covering approximately one million leasable square feet; and approximately 210 acres of undeveloped real estate located in Tulsa, Oklahoma. Helmerich & Payne, Inc. was founded in 1920 and is headquartered in Tulsa, Oklahoma. Goldman Sachs Group started coverage on shares of Helmerich & Payne (NYSE:HP) in a research report report published on Sunday morning, Marketbeat.com reports. The firm issued a neutral rating and a $65.00 price target on the oil and gas company’s stock. In late 2018 oil suddenly dipped into bear market territory, once again showing investors how volatile the key energy commodity can be. But in both good oil markets and bad, oil companies are always looking for an edge. Helmerich & Payne, Inc. (NYSE:HP) has the expertise and technology to help its customers stay at the forefront of the industry, and that, in turn, should ensure this nearly 100-year-old company's success for years to come. Summit Midstream Partners, LP ("SMLP" or the "Partnership") is a Delaware limited partnership that completed its initial public offering ("IPO") on October 3, 2012. Summit Midstream Partners, LLC ("Summit Investments") is a Delaware limited liability company and the predecessor for accounting purposes (the "Predecessor") of SMLP. References to the "Company," "we," or "our," when used for dates or periods ended on or after the IPO, refer collectively to SMLP and its subsidiaries. References to the "Company," "we," or "our," when used for dates or periods ended prior to the IPO, refer collectively to Summit Investments and its subsidiaries. For additional information, see Note 1 to the consolidated financial statements. Item 1. Advisors' Opinion: Exxon is also working with Summit Midstream Partners (NYSE:SMLP) on the development of the Double E pipeline, which is a regional gas pipeline in the Permian. Exxon not only signed up to be a major shipper on Double E but has the option to acquire a 50% interest in the project. That equity stake means Exxon could help fund as much as half of the construction costs, which would ease the financial burden on the cash-strapped Summit Midstream. While Summit Midstream has yet to sanction the project, the company believes it will soon have enough shippers to move forward, which puts it on track to have the pipeline in service by the second quarter of 2021. Units of Summit Midstream Partners (NYSE:SMLP) were down more than 15% as of 10 a.m. EST on Tuesday after the master limited partnership (MLP) unveiled a string of strategic actions aimed at improving its financial position. Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. The company's Performance Chemicals segment offers brominated flame retardants under the Saytex brand; mineral-based flame retardants under the Martinal and Magnifin brands; and elemental bromine, alkyl bromides, inorganic bromides, brominated powdered activated carbon, and bromine fine chemicals that are used in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, paper manufacturing, water purification, beef and poultry processing, and various other industrial applications. This segment also provides tertiary amines for surfactants, biocides, disinfectants, and sanitizers; aluminum oxides for use in various refractory, ceramic, and polishing applications; plastic and other additives comprising curatives; and supplies fine chemistry products and performance chemicals for pharmaceutical and agricultural use, as well as offers custom manufacturing, research, and chemical scale-up services for companies. Its Catalyst Solutions Segment provides refinery catalysts, such as hydroprocessing catalysts, fluidized catalytic cracking catalysts, and additives. This segment also offers performance catalyst solutions, including organometallic co-catalysts and metallocene components and co-catalysts; single-site catalysts; Ziegler-Natta catalysts under the Advantage brand; electronic materials consisting of metal organic products and other products; and chemical catalysts used in the chemical industry. The company serves petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, crop protection, food safety, and custom chemistry service markets. Albemarle Corporation was founded in 1994 and is headquartered in Baton Rouge, Louisiana. A few years ago, Albemarle (NYSE:ALB) drew up a forecast of global lithium demand growth from 2015 to 2025. The internal analysis from the world's leading lithium producer estimated the world would need 400,000 metric tons of lithium carbonate equivalent (LCE) by 2025, which marked a healthy growth rate from the 175,000 metric tons of LCE consumed the year the projection was made. Some analysts were skeptical. Some even called the company crazy. Growth stocks are a difficult breed, often requiring investors to venture into complicated and technically challenging sectors and niches. That is exactly the case with MongoDB (NASDAQ:MDB), a tech company that offers a database that can handle unstructured data. But our contributors have also made sure in this article to include a couple of names that don't require a computer science degree to understand, like Axon Enterprise (NASDAQ:AAXN), which makes stun guns and body cameras for law enforcement; and Albemarle (NYSE:ALB), which is focused on providing lithium for electric vehicles. All three have huge growth prospects, and recent sell-offs for two of them offer what look like discounted prices today. Shares of Albemarle (NYSE:ALB) rose 13% in February, according to data provided by S&P Global Market Intelligence. That big gain came in the wake of the specialty chemicals company reporting its earnings on Feb. 20. If you are looking at the materials space, then you've probably heard of giant and diversified DowDuPont Inc. (NYSE:DWDP), which at this point is really three companies in one. You've likely also seen the meteoric rise and fall of lithium, a key industrial metal on which Albemarle Corporation (NYSE:ALB) is increasingly focused. Both stories here are interesting, but is either of these tales compelling enough to make one stock a better buy than the other? Provident Financial Holdings, Inc. operates as the holding company for Provident Savings Bank, F.S.B. that provides community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its deposit products include checking accounts, savings accounts, money market accounts, and time deposits; and loan portfolio comprises single-family, multi-family, commercial real estate, construction, commercial business, consumer, and other real estate loans. The company also originates, purchases, and sells single-family mortgage loans, including second mortgages and equity lines of credit. In addition, it provides investment and trustee services for real estate transactions. The company operates through 14 full-service banking offices in Riverside County and 1 full-service banking office in San Bernardino County. Provident Financial Holdings, Inc. was founded in 1956 and is headquartered in Riverside, California. Provident Financial (NASDAQ:PROV) and TRINITY BK N A/SH (OTCMKTS:TYBT) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends. E*TRADE Financial (NASDAQ: ETFC) and Provident Financial (NASDAQ:PROV) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends. News articles about Provident Financial (NASDAQ:PROV) have been trending somewhat negative this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Provident Financial earned a daily sentiment score of -0.02 on Accern’s scale. Accern also assigned news articles about the financial services provider an impact score of 45.9215692366566 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future. Capricor Therapeutics, Inc., incorporated on January 26, 2007, is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease, with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development, which include CAP-1002, CAP-1001, CSps, Exosomes, Cenderitide (CD-NP) and CU-NP. The Company's technology is based in cardiospheres (CSps), which are multi-cell clusters of cardiac derived cells. The Company's product candidate, the cardiosphere-derived cells (CDC), is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source). CAP-1002 The Company's product candidate consists of allogeneic cardiosphere-derived cells. The Company is testing CAP-1002 in Capricor's ALLSTAR Phase I/II clinical trial. It is a dual cohort clinical trial that has two independently recruiting strata: the first are patients who have recently experienced a myocardial infarction (30-90 days post myocardial infarction); the second are patients who have suffered an myocardial infarction within one year (90 days to one-year post MI) to see if the cells can reduce the size of older, more established scar. CAP-1001 CAP-1001 consists of autologous CDCs. This product was used in the Phase I CADUCEUS clinical trial. The data from CADUCEUS, using autologous CDCs, demonstrate that the cells are effective in reducing scar within several months of a heart attack. Cardiospheres CSps are multicellular clusters called cardiospheres, a 3D micro-tissue from which CDCs are derived. It has shown healing effects in pre-clinical models of heart failure. The Company considers the CSps as a product. Exosomes Exosomes are nano-sized, membrane-enclosed vesic! les, that are filled with select molecules, including proteins and microRNAs, which, when released send messages to neighboring cells to regulate cellular functions. Exosomes act as a transport vehicle out of the cell for microRNA, other fragments of genetic material and proteins that act as messengers between cells, providing regulatory function for many cell processes, including inflammation, angiogenesis, programmed cell death (apoptosis) and scarring. Cenderitide Cenderitide (CD-NP) belongs to a class of drugs called natriuretic peptides. Cenderitide is designed as an outpatient therapy to be delivered continuously using a validated subcutaneous infusion pump for up to 90 days (the post-acuteperiod) following a hospital admission for Acute Decompensated Heart Failure (ADHF). CU-NP CU-NP is a pre-clinical rationally-designed natriuretic peptide. It consists of amino acid chains identical to those produced by the human body, the ring structure of C-type natriuretic peptide (CNP), and the N- and C-termini of Urodilatin (URO). CU-NP is formulated and manufactured by third parties and they provide the Company with the devices and other products necessary to administer it. Media headlines about Capricor Therapeutics (NASDAQ:CAPR) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Capricor Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.8406921113539 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future. We are a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. Our current product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space, or SCS, adjacent to the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With our proprietary microinjector, drugs are injected into and spread within and through the suprachoroidal space, or SCS, which is the space located between the choroid and the outer protective layer of the eye known as the sclera. Advisors' Opinion: Mirati Therapeutics (NASDAQ:MRTX) and Clearside Biomedical (NASDAQ:CLSD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have earned a consensus recommendation of “Buy” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $22.40. Clearside Biomedical (NASDAQ:CLSD) is scheduled to release its earnings data before the market opens on Wednesday, August 8th. Analysts expect Clearside Biomedical to post earnings of ($0.57) per share for the quarter. MetLife Investment Advisors LLC purchased a new position in shares of Clearside Biomedical Inc (NASDAQ:CLSD) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,859 shares of the company’s stock, valued at approximately $117,000. As of December 2017, Greenlight Re's major (10%+) long positions were General Motors (GM), Brighthouse Financial (BHF), gold (GLD), Bayer (OTCPK:BAYZF), and Mylan (MYL). It also holds a long position in Micron (MU), which was the best positive contributor to its portfolio in the first quarter of 2018. These long positions were balanced by shorts in Tesla (TSLA), Netflix (NFLX), and other "bubble basket" stocks. The portfolio is also short Assured Guaranty (AGO), a municipal bond insurer, a position which is hedged by a simultaneous long in Puerto Rican debt. Overall, the portfolio is 93% gross long and 65% gross short. Unlike most insurance portfolios, just 0.5% of investments are in debt instruments and, in fact, Greenlight Re's short portfolio was 11% allocated to sovereign debt. For the third quarter, the company reported cash and equivalents of $470.4 million, while net income came in at $50 million (includes a gain of $78.7 million from the Immunomedics' warrant). Without the one-time gain, its loss of $28.7 million would still be an improvement over net loss of $31.8 million for the same quarter last year. For the fourth quarter, the company is guiding for ADCETRIS sales in the range of $82 million to $84 million (total revenue of $128 million to $130 million). In addition to the growing opportunity for ADCETRIS (peak sales in excess of $1 billion) and the intriguing prospects of tucatinib, the company has a promising pipeline of ADC candidates and immuno-oncology assets. Partnered programs with the likes of AbbVie (NYSE:ABBV), Astellas (OTCPK:ALPMY), Genmab (OTCPK:GMXAY), Bayer (OTCPK:BAYZF), Genentech and many more also lend additional credibility to the story.Top 10 Low Price Stocks To Buy Right Now: Corindus Vascular Robotics, Inc.(CVRS)
Top 10 Low Price Stocks To Buy Right Now: Citigroup Inc.(C)
Top 10 Low Price Stocks To Buy Right Now: Helmerich & Payne, Inc.(HP)
Top 10 Low Price Stocks To Buy Right Now: Summit Midstream Partners, LP(SMLP)
Top 10 Low Price Stocks To Buy Right Now: Albemarle Corporation(ALB)
Top 10 Low Price Stocks To Buy Right Now: Provident Financial Holdings, Inc.(PROV)
Top 10 Low Price Stocks To Buy Right Now: Capricor Therapeutics, Inc.(CAPR)
Top 10 Low Price Stocks To Buy Right Now: Clearside BioMedical, Inc. (CLSD)
Top 10 Low Price Stocks To Buy Right Now: Bayer Aktiengesellschaft (BAYZF)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates. Advisors' Opinion:
No comments:
Post a Comment